reports
MoneySupermarket.com: 1 director
A director at MoneySupermarket.com sold 21,397 shares at 235p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
RIT Capital Partners: 1 director
A director at RIT Capital Partners bought 1,013 shares at 1,962p and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Redrow: 1 director
A director at Redrow sold 33,958 shares at 697p and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close...
Carrs Group: 1 director
A director at Carrs Group maiden bought 37,254 shares at 136p and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
BDO Unibank Inc: 2 directors
Two Directors at BDO Unibank Inc bought 40,000 shares at between 141.942PHP and 143.250PHP. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing Authorization of Trunerox™ in Colombia by INVIMA for Patients with LGS and DS in Colombia. TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products i...
Net Asset Value(s)
Net Asset Value(s) 14 May 2024 HARGREAVE HALE AIM VCT PLC NAV announcement As at close of business on 10 May 2024, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc was as follows: NAV per Ordinary share of 1p – 44.66 pence. END For further information, please contact: JTC (UK) Limited Susan Fadil 5Uloma Adighibe 7 LEI: 213800LRYA19A69SIT31
OFFENTLIGGØRELSE AF ANMODNING OM AFNOTERING AF INTERMAIL A/S' AKTIER F...
OFFENTLIGGØRELSE AF ANMODNING OM AFNOTERING AF INTERMAIL A/S' AKTIER FRA NASDAQ COPENHAGEN A/S Selskabsmeddelelse nr. 26-2023/2414. maj 2024 OFFENTLIGGØRELSE AF ANMODNING OM AFNOTERING AF INTERMAIL A/S' AKTIER FRA NASDAQ COPENHAGEN A/S København, Danmark, 14. maj 2024 InterMail A/S' ("InterMail") bestyrelse har i dag, efter anmodning fra CapHold inv 4 ApS ("CapHold"), besluttet at anmode Nasdaq Copenhagen A/S ("Nasdaq Copenhagen") om at slette InterMails aktier (ISIN DK0010212224) fra handel og officiel notering på Nasdaq Copenhagen. Forudsat at Nasdaq Copenhagen accepterer begæringen, ...
DSV, 1108 - SHARE BUYBACK IN DSV A/S
DSV, 1108 - SHARE BUYBACK IN DSV A/S Company Announcement No. 1108 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save fo...
NEURONES : Mise à disposition des informations relatives à l’Assemblée...
NEURONES : Mise à disposition des informations relatives à l’Assemblée Générale Mixte du 6 juin 2024 INFORMATION PRESSERubrique : Assemblée Générale Nanterre, le 14 mai 2024 MODALITES DE MISE A DISPOSITION OU DECONSULTATION DES INFORMATIONS RELATIVESA L’ASSEMBLEE GENERALE MIXTE DU 6 JUIN 2024 L’Assemblée Générale Mixte des actionnaires de NEURONES se tiendra le jeudi 6 juin 2024, à 12h00, au siège social, 205 avenue Georges Clemenceau – 92000 Nanterre. L’avis préalable, comportant l’ordre du jour et le texte des résolutions proposées par le Conseil d’Administration, a été publié a...
Rheinmetall AG: 1 director
A director at Rheinmetall AG bought 1,950 shares at 517.463EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
JDC Group AG: 1 director
A director at JDC Group AG bought 2,346 shares at 23.438EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Gain Therapeutics Reports Financial Results for First Quarter 2024 and...
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date Announced Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Tri...
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch G...
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America Merrill Lynch Global Healthcare Conference 2024 in Las Vegas, NV on Wednesday, May 15 at 3:00 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentatio...
Xilio Therapeutics Announces Pipeline and Business Updates and First Q...
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer (MSS CRC) in the third quarter of 2024 Plan to report clinical data for XTX101 and XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 Advancing research-stage pipeline of tumor-activated bispecifics and immune cell engagers Anticipate cash runway into the second quarter of 2025 WALTHAM, Mass., May 14...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Z...
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML – Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in early 2025 – – Breakthrough Therapy Designation to enable expedited review by FDA – SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has completed enrollment of 85 patients in the Phase 2 portion of ...
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Co...
Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis 12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an increase on placebo Improvement in FVC and reduction in cough severity reported in bexotegrast-treated patients at all timepoints compared to placebo Bexotegrast 160 mg was well tolerated over 12 weeks of treatment with no serious adverse events and no discontinuations ...
Batteh Named Saia’s Chief Financial Officer
Batteh Named Saia’s Chief Financial Officer JOHNS CREEK, Ga., May 14, 2024 (GLOBE NEWSWIRE) -- Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today announced that Matthew Batteh has been promoted to Executive Vice President and Chief Financial Officer and Secretary, effective immediately. In this position, he will lead Saia’s finance, pricing, accounting and treasury functions and will work with other key members of Saia’s management team to execute Saia’s long-term vision. “...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial R...
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ET LITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plans to release its first quarter 2024 fi...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring As...
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan – Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – – Validated in standalone and multi-reader, multi-case clinical studies conducted by world-renowned experts – – Urologists testing this TULSA-AI module improved their segmentation accuracy and were 32% faster in their contours – TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:P...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.